AbbVie has announced results from its Phase 2 EMPOWER-1 and EMPOWER-2 trials evaluating emraclidine, a once-daily oral monotherapy for adults with schizophrenia experiencing acute psychotic episodes. Unfortunately, the trials did not meet their primary endpoint, failing to demonstrate statistically significant improvement in the Positive and Negative Syndrome Scale (PANSS) total score compared to placebo at week six.

Despite the setback, emraclidine was well-tolerated, with a safety profile consistent with earlier Phase 1b data. Common adverse events included headache, dry mouth, and dyspepsia, with incidence rates comparable across treatment and placebo groups.

Trial Snapshot

Dr. Roopal Thakkar, AbbVie’s Chief Scientific Officer, acknowledged the disappointment but emphasized the company’s commitment to advancing neuroscience research:

Looking Ahead

While emraclidine’s efficacy remains uncertain, its tolerability and safety profile may justify further investigation, potentially in combination therapies or alternative dosing strategies. AbbVie’s recent acquisition of Cerevel Therapeutics also expands its neuroscience pipeline, offering new avenues for treating psychiatric and neurological disorders.

Schizophrenia remains a complex and underserved condition, and setbacks like these underscore the challenges—and the urgency—of developing effective treatments.